US Pharma MarketingAstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off, with an FDA approval Monday that also advances the British pharma’s goal to strike $80 billion in revenue by the end of the decade. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending…
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off, with an FDA approval Monday that also advances the British pharma’s goal to strike $80 billion in revenue by the end of the decade.
Source: FiercePharma